Author:
Jiménez David,Rodríguez Carmen,Pintado Beatriz,Pérez Andrea,Jara-Palomares Luis,López-Reyes Raquel,Ruiz-Artacho Pedro,García-Ortega Alberto,Bikdeli Behnood,Lobo José Luis,
Abstract
BackgroundA recent trial showed that management driven by prognostic assessment was effective in reducing the length of stay (LOS) for acute stable pulmonary embolism (PE). The efficacy and safety of this strategy in each subgroup of risk stratification remains unknown.MethodsWe conducted a post-hoc analysis of the randomized IPEP study to evaluate the effect of a management strategy guided by early use of a prognostic pathway in the low- and intermediate-high risk subgroups defined by the European Society of Cardiology (ESC) model. These subgroups were retrospectively identified in the control arm. The primary outcome was LOS. The secondary outcomes were 30-day clinical outcomes.ResultsOf 249 patients assigned to the intervention group, 60 (24%) were classified as low-, and 30 (12%) as intermediate-high risk. Among 249 patients assigned to the control group, 66 (27%) were low-, and 13 (5%) intermediate-high risk. In the low-risk group, the mean LOS was 2.1 (±0.9) days in the intervention group and 5.3 (±2.9) days in the control group (P < 0.001). In this group, no significant differences were observed in 30-day readmissions (0% vs. 3.0%, respectively), all-cause (0% vs. 0%) and PE-related mortality rates (0% vs. 0%), or severe adverse events (0% vs. 1.5%). In the intermediate-high risk group, the mean LOS was 5.3 (±1.8) days in the intervention group and 6.5 (±2.5) days in the control group (P = 0.08). In this group, no significant differences were observed in 30-day readmissions (3.3% vs. 3.0%, respectively), all-cause (6.7% vs. 7.7%) and PE-related mortality rates (6.7% vs. 7.7%), or severe adverse events (16.7% vs. 15.4%).ConclusionThe use of a prognostic assessment and management pathway was effective in reducing the LOS for acute PE without comprising safety across subgroups of risk stratification.Clinical Trial Registration[ClinicalTrials.gov], Identifier [NCT02733198].
Funder
Instituto de Salud Carlos III
Subject
Cardiology and Cardiovascular Medicine
Reference22 articles.
1. Trends in mortality related to pulmonary embolism in the European region, 2000-15: analysis of vital registration data from the WHO mortality database.;Barco;Lancet Respir Med.,2020
2. Pulmonary embolism hospitalization, readmission, and mortality rates in US older adults, 1999-2015.;Bikdeli;JAMA.,2019
3. Thrombosis: a major contributor to global disease burden.;Raskob;Arterioscler Thromb Vasc Biol.,2014
4. Acute pulmonary embolism: an update on diagnosis and management.;Rahimtoola;Curr Probl Cardiol.,2005
5. Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000-18: an analysis of the WHO mortality database and of the CDC multiple cause of death database.;Barco;Lancet Respir Med.,2020
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献